Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

PARP1 inhibition sensitizes AML to CD123 CAR-NK cells via immunophenotypic remodeling

View Full Paper
Ask AI
Bookmark
Share

Authors

SRShalini RamachandranASAnna StangerFGF Gierschek

Discussion

Loading...

Member takes

Overview

Cytotoxicity improved with PARP1 inhibition in acute myeloid leukemia, suggesting a promising combination therapy approach.

Key Points

  • Inhibition of PARP1 significantly enhanced cytotoxicity of CD123 CAR-NK cells against AML.
  • Cytotoxicity assays revealed more than a 2-fold increase in killing efficiency at low E:T ratios.
  • Chimeric antigen receptor NK cells demonstrated potent killing of CD123high AML cells, though targeting in bone marrow was limited.
  • Combination treatment involving PARP1 inhibition shows potential to improve eradication of therapy-resistant leukemic stem cells.

Cite This Study

Ramachandran et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236dee7https://doi.org/10.1182/blood-2025-2357
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effiefficacy and safety of allogeneic CD123 CAR-NK cell therapy in Relapsed/Refractory Acute Myeloid Leukemia2025 · 3 citations
  2. 2Targeting CD117 with engineered invariant natural killer T cells (iNKT Cells) as a novel approach for acute myeloid leukemia treatment2025
  3. 3CRISPR/Cas9-engineered universal CD123/B7-H3 tandem CAR-T cell for the treatment of acute myeloid leukemia2025 · 3 citations
  4. 4CD123 ‐targeting immunotherapeutic approaches in acute myeloid leukaemia2025 · 11 citations
  5. 5A novel B7-H3-specific binder enables effective CAR T-cell therapy in an Acute Myeloid Leukemia experimental model2025